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A 
body of research has focused on the relation between 
leukocyte telomere length (LTL) and indices of human 
aging, principally those linked to the aging or disease status 
of the cardiovascular system (reviewed in 1–3). Moreover, 
recent studies in elderly twins apparently resolved the con-
troversy  about  whether  LTL  predicts  survival,  as  they 
showed that the co-twin with the shorter LTL was more 
likely to die first (4,5). Thus, LTL might serve as a bio-
marker of human aging.
Most studies of the relation between LTL and indices of 
human health and aging have used the convenient cross- 
sectional  design  (6–11).  The  cross-sectional  design  can 
only infer the pace of age-dependent LTL shortening based 
on the LTL of individuals of different ages; this estimated 
age association may be influenced by factors such as the 
cohort age range and survival effects. There is considerable 
interindividual variation in LTL at any age, commencing at 
birth (12,13). Thus, shortened LTL, for instance, might stem 
from shorter LTL at birth, an accelerated rate of LTL short-
ening afterward (the pace of which is much faster during the 
formative years than during adult life), or both. Accord-
ingly, longitudinal information about LTL attrition in the 
individual should augment understanding of the role of LTL 
dynamics in human aging.
Only a few studies reported LTL dynamics based on lon-
gitudinal analyses and the cohorts examined were followed-
up for less than 15 years (14–19). These studies reported no 
change in LTL and even LTL elongation in a subset of indi-
viduals. Two questions arise: First, is LTL gain a true bio-
logic  phenomenon?  Second,  what  is  the  duration  of 
follow-up required for reliably detecting LTL attrition for a 
given LTL measurement error? This error, which can be es-
timated from the interassay coefficient of variation (CV), 
impacts on determination of the follow-up duration.
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Background.  Leukocyte telomere length (LTL) is considered a biomarker of human aging and based on cross-
sectional studies it shortens with age. However, longitudinal studies reported that many adults display LTL lengthening.
Methods.  Using Southern blots, we compared cross-sectional rates of age-related LTL change across a ~20 year age 
range with those based on longitudinal evaluations in three surveys (S1, S2, and S3) with three time intervals: S1–S2 (5.8 
years), S2–S3 (6.6 years), and S1–S3 (12.4 years). Hierarchical linear modeling was used to explore LTL dynamics using 
LTL data from S1, S2, and S3.
Results.  Cross-sectionally, mean LTL shortenings were 24.6, 25.4, and 23.6 bp/y at S1, S2, and S3, respectively. 
Longitudinally, more variation was observed in the rate of LTL change during the shorter than longer follow-up periods. 
Furthermore, using simple differences in LTL, 14.4% and 10.7% of individuals displayed LTL lengthening during S1–
S2 and S2–S3, respectively, but only 1.5% during S1–S3 (p < 0.001). The estimated mean rate of LTL shortening based 
on averaging empirical Bayes’ estimates of LTL from a parsimonious hierarchical linear modeling model was 31 bp/y 
with a range from 23 to 47 bp/y with none of the participants showing LTL lengthening over the average 12.4 years of 
follow-up.
Conclusions. As aging displays a unidirectional progression, it is unlikely that LTL elongates with age. LTL elonga-
tion in longitudinal studies primarily reflects measurement errors of LTL in relation to the duration of follow-up periods.
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Theoretical considerations suggest that the longer dura-
tion of the follow-up period and the smaller the CV, the 
more credible are the findings of the change in LTL over 
time (20) and the greater the likelihood of detecting deter-
minants of LTL change if they exist in the underlying popu-
lation. We tested this concept with empirical observations in 
the Bogalusa Heart Study (BHS).
Materials and methods
Participants
The BHS is a long-term investigation of the natural his-
tory  of  cardiovascular  disease  (21).  Between  1995  and 
2009, three surveys (S1, S2, and S3) were conducted. LTL 
data were available for the current study in 271 participants, 
who had blood samples collected in all three surveys, that 
is, S1 (age = 19.9–41.5 y), S2 (age = 25.7–46.3 y), and S3 
(age = 31.5–49.9 y). The study protocol was approved by 
Institutional Review Board of Tulane University.
LTL Measurements
We used Southern blots of the terminal restriction frag-
ments, generated by HinfI/RsaI restriction enzymes to mea-
sure LTL (22). The IDs of the three samples (S1, S2, and 
S3) from each of the 271 donors identified them as belong-
ing to the same individual. Besides the IDs, the laboratory 
that measured LTL was blinded with respect to the sequence 
of S1, S2, and S3 and to other characteristics of the subjects.
Assessment of LTL Measurement Error
Two strategies were employed. The first was to examine 
the relation between blind duplicates and the second was to 
examine the relation between laboratory duplicates mea-
sured on different occasions.
The assessment of the measurement error of the blind du-
plicates was performed as follows: During S3, blood sam-
ples  drawn  from  33  randomly  selected  individuals  were 
divided into two aliquots in the field center. One vial was 
labeled with a blind duplicate identification (ID) number 
and the other was labeled with the true ID number. The two 
sets of vials were randomly distributed among all other vi-
als and shipped to the laboratory for LTL measurements. 
The within-subject CV (in percent) was used as an index of 
the LTL measurement error.
Statistical Analysis
Analyses were performed using SAS version 9.1 (SAS 
Institute, Inc., Cary, NC). Comparisons for continuous vari-
ables were made using t tests or when nonnormal using Wil-
coxon  rank  sum  tests  and  for  binary  variables  using 
chi-square tests.
The yearly rate of change (loss or gain) in LTL, expressed 
in bp/y, was computed as the difference between LTL mea-
sured in the pairs of surveys, that is, S1–S2, S2–S3, and 
S1–S3.
Analysis of covariance was performed using general lin-
ear models to test for differences in LTL between African 
Americans  (AfAs)  and  whites  and  between  men  and 
women. The age-related trends of LTL in cross-sectional 
analyses in S1, S2, and S3 were derived separately in linear 
regression models.
Hierarchical linear models (HLMs) using PROC MIXED 
utilized data from all three surveys to estimate the absolute 
LTL over time, allowing each participant to have his or her 
own intercept and slope. Fixed effects for age (at S1, S2, 
and S3), race, baseline smoking status, baseline body mass 
index  (BMI)  and  interactions  with  age  were  evaluated.   
Participant-specific  rates  of  change  in  the  LTL  use  the 
empirical  Bayes’  estimates  of  the  slopes.  Although  the 
range of intervals between actual visits varied, we used the 
estimated  distribution  for  differences  in  LTL  measured   
6 and 12 years apart to estimate the expected percentage of 
subjects to show apparent elongation using the estimated 
mean changes in LTL for each covariate combination and 
the empirical distribution of covariates in this cohort.
The intraclass correlation coefficient was calculated as 
the ratio of between and total variance from the HLM. The 
within-subject  CV is the ratio of the mean to the within-
subject standard deviation from the HLM.
Unless otherwise indicated, data are presented as mean 
(standard deviation).
Results
Cohort Characteristics
Age and follow-up periods of the study cohort are sum-
marized in Table 1. The average age was 31.1 (4.7) years, 
36.8 (4.3) years, and 43.5 (4.4) years for S1, S2, and S3, 
respectively. The mean S1–S2 interval was 5.8 (1.5) years 
and that of S2–S3 was 6.6 (1.0) years. White men had a 
higher BMI than white women, whereas AfA men had a 
lower BMI than AfA women.
Intraclass Correlations and CVs of Duplicate 
Measurements of LTL
The  intraclass  correlation  coefficient  of  LTL  between 
field blind duplicate samples was 0.947 (95% confidence 
intervals: 0.899–0.973). The intraclass correlation coeffi-
cient of LTL between laboratory duplicates was 0.94 (95% 
CI: 0.93–0.95). The CV for the 33 field blind duplicates was 
2.4% (95% confidence intervals: 1.9–3.1) and 2.4% (95% 
confidence intervals: 2.3–2.5) for the laboratory duplicates.
LTL Dynamics in the Cross-sectional Design
Figure 1 displays the cross-sectional data of LTL as a func-
tion of age at S1, S2, and S3. LTL significantly shortened CHEN ET AL. 314
with age (24.6, 25.4, and 23.6 bp/y of age at S1, S2, and S3, 
respectively).
Table 2 presents LTL data by race and sex for S1, S2, and 
S3. AfAs  consistently  displayed  a  longer  LTL  than  did 
whites across the duration of the follow-up. However, there 
was no significant sex effect on LTL in this modest-sized 
cohort.
Table 3 displays a regression model assessing the indi-
vidual (partial R2) and joint effects (model R2) of age, race, 
sex, BMI, and smoking on LTL at S1, S2, and S3. As the age 
range for S1, S2, and S3 in the cross-sectional model was 
restricted to two decades, age explained only 2.01–2.54% 
of  the  variance  of  LTL.  However,  race  explained  9.03–
12.10% of the variance. Sex, as indicated earlier, had little 
effect of LTL, but BMI and smoking status did exert dis-
cernable effects: BMI explained 0.97–2.05% of the LTL 
variation (all statistically significant) and smoking status 
explained  0.64–1.23%  (marginally  or  borderline  signifi-
cance for S1 and S3). Overall, the joint effects of age, race, 
sex, BMI, and smoking explained 13.5–16.7% of the LTL 
variation in the cross-sectional design.
LTL Dynamics in the Longitudinal Design
Figure 2 displays the distribution of the rate of change in 
LTL  among  participants  for  S1–S2,  S2–S3,  and  S1–S3 
based on the subtracting LTL values at the two measure-
ment time points. The mean rates of LTL change, which 
also included a subset that gained LTL during follow-up, 
were a shortening by 31.4, 33.5, and 32.2 bp/y for S1–S2, 
S2–S3, and S1–S3, respectively. There was more variation, 
evident as a wider spread, in the rate of LTL change during 
S1–S2 and S2–S3 than during S1–S3 (Figure 2). Further-
more,  14.4%  and  10.7%  of  individuals  displayed  LTL 
lengthening  during  intervals  S1–S2  and  S2–S3,  respec-
tively, but only 1.5% in interval S1–S3 (p < 0.001 for the 
decline in proportion with longer follow-up).
Table 1.  General Characteristics in S1, S2, and S3
Whites African Americans p for race difference
Males (n = 73) Females (n = 131) Males (n = 19) Females (n = 48)
Males Females Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age at S1 31.8 (4.2) 30.8 (4.8) 31.8 (4.4) 30.4 (5.0) 0.973 0.466
Age at S2 37.5 (4.0) 36.6 (4.4) 37.3 (3.8) 36.4 (4.7) 0.923 0.557
Age at S3 44.0 (4.1) 43.3 (4.5) 44.0 (3.7) 42.9 (4.5) 0.942 0.498
Interval S1–S2 5.7 (1.5) 5.8 (1.5) 5.6 (1.9) 5.9 (1.6) 0.791 0.622
Interval S2–S3 6.5 (1.0) 6.7 (0.9) 6.7 (0.6) 6.6 (1.3) 0.422 0.818
Interval S1–S3 12.1 (1.9) 12.5 (1.7) 12.3 (2.2) 12.6 (1.9) 0.429 0.939
BMI at S1 28.0 (5.3) 25.1 (5.6)** 27.6 (8.7) 30.4 (8.8) 0.307 <0.001
BMI at S2 29.6 (6.0) 26.7 (5.9)** 29.1 (9.5) 32.0 (8.6) 0.385 <0.001
BMI at S3 30.4 (6.0) 27.8 (6.2)** 30.4 (9.7) 33.9 (8.8) 0.345 <0.001
N (%) N (%) N (%) N (%) Males Females
Smokers at S1 18 (25) 41 (31) 9 (47) 15 (31) 0.053 0.995
Smokers at S2 14 (19) 31 (24) 5 (26) 14 (29) 0.494 0.452
Smokers at S3 12 (16) 31 (24) 6 (32) 10 (21) 0.138 0.690
Notes: Testing performed using Wilcoxon rank sum tests for age, interval, and body mass index (BMI) and chi-square tests for current smoking status. Sex 
difference within races: *p < 0.05 (none), **p < 0.01. SD = standard deviation.
Figure 1.  Cross-sectional analysis of leukocyte telomere length (LTL) versus age in the three surveys (S1, S2, and S3). LEUKOCYTE TELOMERE DYNAMICS 315
The correlation coefficient of the rate of change in LTL 
between S1–S2 and S2–S3, adjusted for baseline age, was 
−0.390 (p < 0.0001). When adjusted for both baseline age 
and LTL, the correlation coefficient of rates of change be-
tween the two periods was −0.399 (p < 0.0001). To gain 
further insight into this association, we compared the rate of 
change during S2–S3 in individuals who demonstrated LTL 
elongation (N = 39) during S1–S2 versus those who showed 
LTL shortening (N = 232) during this period. The rate of 
LTL shortening during S2–S3 in individuals who gained 
telomeres in S1–S2 was significantly faster (59.7 (53.2) bp/y) 
compared  with  their  peers  who  showed  LTL  shortening   
during S1–S2 (29.1 (29.4) bp/y; p < 0.0001). We then com-
pared the rate of LTL shortening during S1–S2 in individu-
als with LTL elongation during S2–S3 (N = 29) versus those 
who showed LTL shortening during that time period (N = 
242). Again, the rate of LTL shortening during S1–S2 in 
those individuals who showed LTL lengthening during S2–
S3 was significantly faster (52.7 (37.0) bp/y) than in their 
peers who showed LTL shortening during that period (28.8 
(35.6) bp/y; p = 0.0011).
Among 67 individuals who displayed LTL elongation in 
the original analysis, 66 individuals (N = 37 for S1–S2, N = 
28 for S2–S3, and N = 1 for S1–S3) had sufficient DNA to 
repeat the measurements 7 months after original measure-
ments. The correlation between the first and second sets of 
measurements (each performed in duplicate) was r = 0.932, 
p = 0.0001 (Supplementary Figure 1).
For these individuals, all of whom displayed LTL elon-
gation in the original analysis on repeated LTL measure-
ments  44  individuals  showed  LTL  shortening  and  22 
showed LTL elongation (mean rate of LTL shortening = 
17.2 bp/y).
We used HLMs, which provided mean and participant-
specific estimates of LTL change, to gain a further insight 
into LTL dynamics over the entire duration of the follow-
up. Table 4 displays fixed-effects results from two HLMs, 
which include main effects and interaction effects with age. 
The interaction effects in Model 1 show the estimated ef-
fects of race, sex, smoking, and BMI on the rate of change 
in LTL. Model 2 is a more parsimonious model in which the 
interaction between age and BMI is omitted.
The mean LTL shortening based on averaging empirical 
Bayes’ estimates from Model 2 was 31 bp/y, whereas the 
individual-specific rate of change declined between 23 and 
47  bp/y.  No  participant  was  estimated  to  display  LTL 
lengthening based on the HLM. The individual slopes (em-
pirical Bayes’ estimates) generally fit the observed data for 
both those whose LTL shortened between surveys and those 
who seemed to elongate their LTL. Supplementary Figure 2 
shows a stratified random sample of 12 individuals’ LTLs 
over time; 6 who had consecutive shortening in observed 
LTL values over time and 6 who did not.
Examining the interaction effects in Model 1 showed that 
AfAs displayed a faster rate of LTL shortening than whites 
(by 5.4 bp/y, p = 0.028), women had a slower rate of LTL 
shortening than men (by 4.5 bp/y, p = 0.044), and those that 
reported smoking at S1 had a faster rate of shortening than 
those who did not (by 4.7 bp/y, p = 0.040). BMI was not 
associated with a faster rate of LTL shortening (p = 0.45). 
Although the lack of a significant Age × BMI interaction in 
Model 1 suggests that having a higher BMI at baseline did 
Table 2.  Leukocyte Telomere Length (LTL, kb) in Three Surveys (S1, S2, and S3)
Whites African Americans p for race difference
Males (n = 73) Females (n = 131) Males (n = 19) Females (n = 48)
Males Females Mean (SD) Mean (SD) Mean (SD) Mean (SD)
LTL at S1 7.005 (0.617) 7.114 (0.699) 7.713 (0.656) 7.650 (0.732) <0.001 <0.001
LTL at S2 6.844 (0.645) 6.938 (0.711) 7.525 (0.688) 7.450 (0.769) <0.001 <0.001
LTL at S3 6.612 (0.582) 6.749 (0.711) 7.196 (0.634) 7.215 (0.792) <0.001 <0.001
Note: Testing performed using a t test assuming equal variances. No significance sex differences within race were found. SD = standard deviation.
Table 3.  Regression of Leukocyte Telomere Length (LTL, bp) in Three Surveys (S1, S2, and S3) on Age, Race, Sex, BMI, and Smoking
LTL at S1 LTL at S2 LTL at S3
Independent variable b p Partial R2 Model R2 b p Partial R2 Model R2 b p Partial R2 Model R2
Intercept 7,472.7 <0.001 — — 7,663.8 <0.001 — — 7,363.4 <0.001 — —
Age −21.8 0.013 2.54 — −24.0 0.015 2.14 — −22.1 0.022 2.01 —
Race 641.6 <0.001 12.10 — 628.9 <0.001 10.62 — 553.3 <0.001 9.03 —
BMI −13.6 0.034 1.00 — −17.7 0.006 2.05 — −12.3 0.041 0.97 —
Smoking 177.8 0.049 1.23 16.96 −144.6 0.157 0.64 15.50 −192.1 0.060 1.16 13.55
Notes: A negative regression coefficient denotes a shorter LTL and a positive coefficient denotes a longer LTL. African American = 1, white = 0; smoking yes = 
1, no = 0. BMI = body mass index.CHEN ET AL. 316
not increase the rate of LTL shortening, those persons with 
higher BMI had a shorter LTL (13.6 bp shorter LTL per unit 
higher BMI in Model 2, p = 0.034).
Besides age, race was the single most important determi-
nant of LTL with AfAs having a 590 bp longer LTL at age 
40 years based on Model 2. Because of the significant inter-
action with age, the race difference increases by 5.0 bp for 
each year younger than 40 and diminishes by 5.0 bp for 
each year older than 40.
Expected Percentage of Subjects with Apparent Elongation 
between Visits
Using the results from Model 2, the expected mean (stan-
dard  deviation)  difference  in  LTL  measurements  6  and 
12 years apart is a decrease ranging from 185 (201) to 199 
(201) bp and 375–389 (212) bp, respectively, and we would 
expect that 17.2% of individuals would have apparent LTL 
elongation between interval visits of 6 years and 3.7% be-
tween interval visits of 12 years. The observed percentages 
were actually lower, 10.7%–14.4% for S1–S2 and S2–S3, 
which had a mean interval of approximately 6 years, and 
1.5% for S1–S3, which had a mean interval of approxi-
mately 12 years.
Discussion
Researchers  have  often  suggested  that  a  longitudinal 
evaluation might provide a better understanding than the 
cross-sectional strategy about the connection between LTL 
dynamics and a host of biologic and environmental indices 
(22–26). But, as shown here, technical shortcomings in the 
determination of LTL need to be addressed.
On average, LTL shortening in cross-sectional analyses 
of the adult population at large has been reported to be less 
than 40 bp/y and the reported CV of LTL measurement by 
different methods range between 0.9% and 28% (27–29). 
But as shown in the present study, even a relatively low 
measurement error, expressed in a CV of ~2.5% can result 
in sufficient misclassification.
The error in LTL measurement probably explains why 
during S1–S2 and S2–S3 many more individuals displayed 
LTL elongation than during S1–S3. The negative correla-
tion of rates of LTL shortening between S1–S2 and S2–S3 
Figure 2.  Distribution of yearly rate of change in leukocyte telomere length 
(LTL) for the two consecutive follow-up periods, S1–S2, S2–S3, and the two 
periods combined, S1–S3.
Table 4.  Estimated Fixed Effects from Hierarchical Linear Models 
Using Leukocyte Telomere Length (LTL, bp) from S1 to S3 as the 
Dependent Variable, with Random Effects for the Intercept and Slope
Independent variable b p Value
Model 1
  Intercept 6,834.2 <0.001
  Age −31.7 <0.001
  Race 588.4 <0.001
  Sex 41.8 0.63
  Baseline smoking −218.3 0.017
  Baseline BMI −13.1 0.042
  Age × Race −5.4 0.028
  Age × Sex 4.5 0.044
  Age × Baseline Smoking −4.7 0.040
  Age × Baseline BMI 0.12 0.45
Model 2
  Intercept 6,834.4 <0.001
  Age −31.6 <0.001
  Race 590.0 <0.001
  Sex 41.6 0.63
  Baseline smoking −220.0 0.016
  Baseline BMI −13.6 0.034
  Age × Race −5.0 0.038
  Age × Sex 4.3 0.052
  Age × Baseline Smoking −5.0 0.026
Notes: Age and BMI are centered so the intercept corresponds to age 40 
years and BMI of 27 kg/m2 for Model 1 and age of 40 years for Model 2. Race 
is coded: AfA = 1, white = 0; sex coded women = 1, men = 0; smoking coded 
yes = 1, no = 0. Unstructured covariances were used when fitting the models. 
The bs estimate the increase in LTL for a 1 unit increase in the covariate, with a 
negative coefficient denoting a shorter LTL. For example, for nonsmoking white 
men, the b for age in Model 2 estimates a decrease of 31.6 bp/y. Tests of interac-
tions with age are used to evaluate differences in rates of LTL change by covari-
ates, for example, the b for the Age × Race interaction in Model 2 indicates 
AfAs have a 5.0 bp/y greater rate of LTL shortening. AfA = African American; 
BMI = body mass index. LEUKOCYTE TELOMERE DYNAMICS 317
suggests that individuals with a relatively low rate of LTL 
shortening in one period were prone to display a relatively 
high rate of LTL shortening prior to or after that period. 
This expression of regression to the mean may be a reflec-
tion of laboratory error. Support for this conclusion was 
provided by the repeat LTL measurements in individuals 
who showed LTL elongation. Measurement errors should 
primarily affect results derived from individuals with a rela-
tively slower rate of LTL shortening, that is, those below the 
mean rate of LTL shortening. Repeating LTL measurements 
in samples from these individuals confirmed this supposi-
tion, showing that the majority of them showed LTL short-
ening upon reexamination. The HLMs further strengthened 
the tenet that LTL elongation was mainly, if not solely, the 
outcome  of  telomere  measurement  error.  These  models 
showed that after removing unexplained errors based on all 
LTL measurements during the follow-up period, no indi-
vidual displayed LTL elongation over time.
Although a number of potential biologic causes for LTL 
elongation have been offered to explain the wide swings in 
the rate of LTL change (16) in the general population, some 
of the findings might simply indicate the presence of a large 
measurement error of LTL relative to the magnitude of the 
LTL attrition (ie, a too short follow-up) rather than an ex-
pression of a true biologic phenomenon.
Any  longitudinal  study  that  examines  age-dependent 
LTL shortening provides a slice―a small one under most 
circumstances―of the life span of the individual. In con-
trast, at any given age, the value of LTL represents LTL 
attrition during the entire life course of the individual from 
birth  onward,  only  that  the  considerable  interindividual 
variation in birth LTL renders it difficult to fully appreciate 
that attrition without knowing the individual’s LTL at birth. 
It follows that both the cross-sectional data and longitudi-
nal data of LTL provide incomplete but complementary 
perspectives on the relation between LTL dynamics and 
biologic phenomena of interest. Based on cross-sectional 
and longitudinal evaluations (30–32) and a series of simu-
lations (33), the rate of LTL shortening is very rapid during 
infancy and early childhood. In contrast, the rate of LTL 
shortening during adulthood, on the basis of both the cross-
sectional and longitudinal data, is much slower than during 
early life.
The  effect  of  LTL  shortening  with  age  in  a  cross- 
sectional design depends on the age range and interindivid-
ual variation in LTL of the sample (28,34). The 2.5% or less 
contribution  of  age  to  variation  in  LTL  in  our  cross- 
sectional analysis reflects the relatively narrow age range   
of our cohort at S1, S2, and S3, which was ~20 years, and 
the studied period within the life course (young to mid-
adulthood). In that light, the effects of BMI, smoking, and 
particularly race on LTL based on the cross-sectional analysis 
(Table 3) were considerable.
At birth, LTL is equivalent in boys and girls (13,14), but 
studies  in  adults  have  observed,  with  few  exceptions 
(34,35), that LTL is longer in women than in men (4,7,36–
40). The first cited exception applied to a cross-sectional 
study, which examined healthy aging in highly selected 
participants (age range 16–104 years old) who were free 
of any apparent disease (34). The second cited exception 
was a cross-sectional evaluation of LTL in BHS partici-
pants (35). Nevertheless, in the latter study, a longer LTL 
was observed in women than in men using HphI/MnII in-
stead of HinfI/RsaI restriction enzymes to generate the 
terminal restriction fragments (35). If newborn boys and 
girls have equivalent LTL but on average, women have a 
longer LTL, one would anticipate that either during matu-
ration or adult life, the rate of LTL shortening would be 
slower in women than in men. But a number of cross-sec-
tional analyses and a longitudinal evaluation more than 
6 years (14) were unable to show such sex-related differ-
ences in adults. Bekaert and colleagues (7) did find in a 
cross-sectional study that the rate of LTL shortening was 
slower in women than men and the present study confirms 
this  finding.  HLM  Models  1  and  2  showed  modestly 
slower mean rates (4.5 and 4.3 bp/y) of shortening among 
women compared with men (p = 0.044 and p = 0.052, re-
spectively). As both effects were marginal, they need con-
firmation in larger studies.
An inverse relation between BMI and LTL was observed 
before  (41–44).  Paradoxically,  although  higher  baseline 
BMI was associated with a shorter LTL, it was not associ-
ated with accelerated shortening in this study. We were also 
limited in how we could analyze the BMI, as the change in 
BMI  was  relatively  small  across  the  follow-up  period. 
Again, larger studies with follow-up periods during differ-
ent phases of the human life span with a broader range of 
BMI values are necessary to more fully understand the ef-
fect of age and BMI on the rate of LTL shortening.
Several cross-sectional evaluations of different cohorts, in-
cluding the BHS, observed that smokers had a shorter LTL 
than nonsmokers (16,37,38,41) but did not show that smok-
ers displayed an accelerated LTL shortening during a 6-year 
longitudinal evaluation in BHS participants (16). Applying 
HLM  to  data  from  three  measurement  time  points  that 
spanned approximately 12.4 years, we were able to show that 
individuals reporting smoking at baseline have shorter LTL 
and have an accelerated LTL shortening, but again, this re-
quires confirmation in large-scale longitudinal studies.
Finally, the HLM models showed that the racial differ-
ence in LTL narrowed with age in line with the faster LTL 
shortening in adult AfAs than whites, a phenomenon we ob-
served in a large cross-sectional study of age range that cov-
ers seven decades (35).
In conclusion, longitudinal evaluation of LTL provides 
an important additional dimension to our understanding of 
LTL dynamics. Our data strongly suggest that LTL elonga-
tion with age is an unlikely occurrence and is probably a 
measurement artifact. Analysis of longitudinal data should 
use statistical methods that estimate effects after accounting CHEN ET AL. 318
for unexplained error. Moreover, researchers need to recog-
nize the limitation of current methods of telomere length 
measurements.  That  being  said,  well-designed,  properly 
powered studies using techniques that minimize measure-
ment error of LTL can provide valuable insight into the role 
of telomere biology in human aging.
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